Sam (for Matthew O'Brien)'s questions to Transmedics Group Inc (TMDX) leadership • Q1 2025
Question
An analyst on behalf of Matthew O'Brien inquired about the anticipated impact of the next-generation heart and lung clinical trials on service revenues and margins, and also sought reassurance on the liver business's durability against upcoming competition.
Answer
Executive Waleed Hassanein confirmed that the upcoming trials will generate product revenue but stated that potential service revenue from the control arm is still under discussion. On the liver business, he reiterated confidence, emphasizing that the OCS platform's superior clinical outcomes and cost-efficiency are driving market adoption and that competitors must prove their value proposition, which he believes is lacking.